The PalomAGE study

The standard treatment for hormone receptor-positive HER2-negative advanced breast cancer involves combining endocrine therapy with a CDK4/6 inhibitor. However, clinical trials often underrepresent women aged 70 and older, despite this age group accounting for more than 30% of breast cancer diagnoses. 

To address this gap, the PalomAGE study was conducted in France as a real-world assessment of the feasibility of using palbociclib in combination with endocrine treatment, specifically in women aged 70 and older with hormone receptor-positive HER2-negative advanced breast cancer. The study aimed to evaluate the effectiveness and tolerability of this treatment regimen in older patients. 

During this year’s ASCO poster session, the results of the PalomAGE study were presented. Prof. Duhoux, a medical oncologist from the Cliniques Universitaires St. Luc Brussels, engaged in a discussion with Dr Etienne Brain from Institut Curie, Paris, regarding the study’s findings. The discussion focused on the implications and significance of the study’s results, providing valuable insights into the use of palbociclib combined with endocrine therapy in older women with advanced breast cancer. 

With the educational support of: